About this trial
EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.
Eligibility criteria
Qualifiers
18-100 years old
Biologically born female
Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)
No cancer diagnosis (Arm 2-health control)
Disqualifiers
less than 18 years of age
Biologically born male
Incarcerated at the time of participation
Trial design
Treatments tested in this trial
- blood draw
- Gene sequencing